ResMed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2017
Revenue increased 7% to $556.7 million; up 8% on a constant currency basis
GAAP diluted earnings per share of $0.71; non-GAAP diluted earnings per share of $0.77
Operating cash flow of $140.3 million in the fourth quarter
Quarterly dividend increased by 6% to $0.35 per share

SAN DIEGO, Aug. 1, 2017 /PRNewswire/ -- ResMed Inc. (NYSE: RMD) today announced results for its quarter ended June 30, 2017. Revenue for the quarter was $556.7 million, a 7 percent increase compared to the same period of the prior year. Excluding the contribution from the Brightree business acquired in April 2016, revenue for the quarter was $520.5 million, a 6 percent increase.   

"We finished the year with solid constant currency revenue growth, fuelled by sales of our devices, masks, and software-as-a-service revenue from Brightree," said Mick Farrell, ResMed's chief executive officer.

"During the quarter, we made two acquisitions to augment our Brightree solutions, we presented and published results from clinical studies in sleep and COPD, and we launched two new products: AirTouch - the softest CPAP mask from ResMed; and AirMini - the world's smallest CPAP."

Farrell concluded, "Our board of directors has declared a 6 percent increase in our dividend this quarter, reflecting confidence in our long-term outlook and 2020 strategy. We are positioned for another great year ahead, as we deliver products and solutions that improve patient outcomes, create efficiencies for our customers, lower overall healthcare system costs and deliver cash to our shareholders."

Analysis of fourth quarter results

Fourth quarter revenue in the Americas was $350.2 million, an 8 percent increase over the same period of the prior year. This included Brightree revenue of $36.2 million. Excluding Brightree, revenue in the Americas was $314.0 million, a 6 percent increase over the prior year. Revenue in combined EMEA and APAC was $206.5 million, an increase of 9 percent on a constant currency basis, compared to the same period of the prior year.

Gross margin in the fourth quarter was 58.2 percent, higher than the prior year's quarter gross margin of 58.1 percent. The improvement in gross margin compared to prior year's quarter was due to manufacturing and procurement efficiencies partially offset by declines in average selling prices and changes in product mix.

Income from operations for the quarter was $127.4 million, a 7 percent increase compared with the quarter ended June 30, 2016. Non-GAAP income from operations for the quarter was $139.1 million, a 3 percent increase compared to the same period of the prior year. 

Selling, general and administrative expenses were $147.9 million, a 10 percent increase over the same period in the prior year, also an 11 percent increase on a constant currency basis. SG&A expenses increased to 26.6 percent of revenue in the quarter, compared with 25.8 percent reported in the quarter ended June 30, 2016.  

Research and development expenses were $36.7 million, or 6.6 percent of revenue. R&D expenses increased by 7 percent compared with the same period last year, or a 6 percent increase on a constant currency basis.

Amortization of acquired intangible assets was $11.8 million during the quarter, a decrease of $0.9 million compared with the same period last year. Stock-based compensation costs incurred during the quarter of $11.7 million consisted of expenses associated with employee equity grants, and our employee stock purchase plan. 

Net income for the quarter was $101.6 million, a 22 percent increase compared to the same period of the prior year. Non-GAAP net income was $109.6 million, a 5 percent increase compared to the prior year.

Non-GAAP measures adjust for amortization of acquired intangibles, the one-time deferred revenue fair value adjustment, the SERVE-HF accrual release and acquisition related expenses.

GAAP diluted earnings per share for the quarter increased 20 percent to $0.71.  Non-GAAP diluted earnings per share of $0.77 were 4 percent higher compared with the same period of the prior year. 

Cash flow from operations for the quarter was $140.3 million compared to net income in the current quarter of $101.6 million.

Analysis of fiscal year 2017 results

Revenue for the year increased 12 percent over the prior year to $2.1 billion, or a 13 percent increase on a constant currency basis.

Income from operations for the year was $425.8 million, a 1 percent decrease over the prior year. Non-GAAP income from operations for the year was $508.4 million, a 9 percent increase compared to the prior year.

Non-GAAP measures adjust for amortization of acquired intangibles, the Astral battery field safety notification expenses, restructuring expenses, litigation settlement expenses, acquisition related expenses, the one-time deferred revenue fair value adjustment and the SERVE-HF accrual release.

Net income for the year was $342.3 million, a 3 percent decrease over the prior year. Non-GAAP net income was $401.3 million, a 6 percent increase compared to the prior year.

GAAP diluted earnings per share decreased 4 percent to $2.40. Non-GAAP diluted earnings per share for the year was $2.82, a 5 percent increase compared with the prior year.

Cash flow from operations for the year was $414.1 million. During the year we paid $186.3 million in dividends and repaid $95.0 million of our outstanding debt.

Dividend program

The ResMed board of directors today declared a 6 percent increase in the quarterly cash dividend to $0.35 per share. The dividend will have a record date of August 17, 2017, payable on September 21, 2017. The dividend will be paid in U.S. currency to holders of ResMed's common stock trading on the New York Stock Exchange. Holders of Chess Depositary Instruments trading on the Australian Securities Exchange will receive an equivalent amount in Australian currency, based on the exchange rate on the record date, and reflecting the 10:1 ratio between CDIs and NYSE shares. The ex-dividend date will be August 16, 2017 for common stock holders and for CDI holders. ResMed has received a waiver from the ASX's settlement operating rules, which will allow ResMed to defer processing conversions between its common stock and CDI registers from August 16, 2017 through August 17, 2017 inclusive. 

Webcast details

ResMed will discuss its financial and business results and outlook on its webcast at 1:30 p.m. U.S. Pacific Time today. The live webcast of the call can be accessed on ResMed's Investor Relations website at investor.resmed.com.  Please go to this section of the website and click on the icon for the "Q4 2017 earnings webcast" to register and listen to the live webcast. The online archive of the broadcast will be available on ResMed's website after the live call. In addition, a telephone replay of the conference call will be available approximately two hours after the call by dialing 800-585-8367 (U.S.) and +1 416-621-4642 (outside U.S.) and entering a passcode of 48372777. The telephone replay will be available until August 15, 2017.

About ResMed

ResMed (NYSE:RMD) changes lives with award-winning medical devices and cutting-edge cloud-based software applications that better diagnose, treat and manage sleep apnea, chronic obstructive pulmonary disease (COPD) and other chronic diseases. ResMed is a global leader in connected care, with more than 3 million patients remotely monitored every day. Our 6,000-strong team is committed to creating the world's best tech-driven medical device company – improving quality of life, reducing the impact of chronic disease, and saving healthcare costs in more than 120 countries.

Safe harbor statement

Statements contained in this release that are not historical facts are "forward-looking" statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements – including statements regarding ResMed's projections of future revenue or earnings, expenses, new product development, new product launches and new markets for its products and the integration of acquisitions – are subject to risks and uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. Additional risks and uncertainties are discussed in ResMed's periodic reports on file with the U.S. Securities & Exchange Commission.  ResMed does not undertake to update its forward-looking statements.

Contacts:


For Investors

For News Media

Agnes Lee

Alison Graves

O: 858-836-5971

O: 858-836-6789

investorrelations@resmed.com 

news@resmed.com

 

ResMed Inc and Subsidiaries

Condensed Consolidated Statements of Income (Unaudited)

(In thousands, except per share data)

















Three Months Ended



Twelve Months Ended




June 30,



June 30,




2017



2016



2017



2016















Net revenue

$

556,686


$

518,647


$

2,066,737


$

1,838,713


Cost of sales


232,910



217,560



859,922



775,020


Astral field safety notification expenses (1)


-



-



5,070



-


SERVE-HF accrual release (1)


-



(402)



-



(2,804)


Gross profit


323,776



301,489



1,201,745



1,066,497















Operating expenses:













Selling, general and administrative


147,940



133,929



553,968



482,593


Research and development


36,706



34,380



144,467



118,651


Restructuring expenses (1)


-



-



12,358



6,914


Litigation settlement expenses (1)


-



-



8,500



-


Acquisition related expenses (1)


-



1,914



10,076



5,464


Amortization of acquired intangible assets (1)


11,769



12,629



46,578



23,923


Total operating expenses


196,415



182,852



775,947



637,545


Income from operations (1)


127,361



118,637



425,798



428,952















Other income (expenses), net:













Interest income (expense), net


(3,310)



(2,374)



(11,151)



5,654


Other, net


(2,428)



1,168



4,096



4,960


Total other income (expenses), net


(5,738)



(1,206)



(7,055)



10,614


Income before income taxes


121,623



117,431



418,743



439,566


Income taxes excluding ASU 2016-09 (2)


22,194



35,572



82,530



98,329


Income taxes relating to ASU 2016-09 (2)


(2,184)



(1,267)



(6,071)



(11,172)


Total income taxes


20,010



34,305



76,459



87,157


Net income (1)

$

101,613


$

83,126


$

342,284


$

352,409















Basic earnings per share (2)

$

0.72


$

0.59


$

2.42


$

2.51


Diluted earnings per share (2)

$

0.71


$

0.59


$

2.40


$

2.49


Non-GAAP diluted earnings per share (1) (2)

$

0.77


$

0.74


$

2.82


$

2.68















Basic shares outstanding


142,019



140,551



141,360



140,242


Diluted shares outstanding (2)


143,119



141,654



142,453



141,669

















(1)

See the reconciliation of non-GAAP financial measures in the table at the end of the press release.



(2)

As a result of the adoption of ASU 2016-09 "Improvements to Employee Share-Based Payment Accounting" during the quarter ended June 30, 2016 we now recognize an income tax impact relating to share-based payment transactions. The income taxes for the three and twelve months ended June 30, 2016 have been restated to reflect the adoption of the standard as the benefit was previously recorded as a reduction to Additional Capital.   

 

ResMed Inc And Subsidiaries

Condensed Consolidated Balance Sheets (Unaudited - In thousands)











June 30,



June 30,




2017



2016


ASSETS







Current assets:







Cash and cash equivalents

$

821,935


$

731,434


Accounts receivable, net


450,530



382,086


Inventories


268,319



224,456


Prepayments and other current assets


103,219



81,743


Total current assets


1,644,003



1,419,719


Property, plant and equipment, net


394,241



384,276


Goodwill


1,064,874



1,059,245


Other intangibles, net


261,800



299,808


Deferred income taxes and other non-current assets


103,569



93,657


Total non-current assets


1,824,484



1,836,986


Total assets

$

3,468,487


$

3,256,705


LIABILITIES AND STOCKHOLDERS' EQUITY:







Current liabilities:







Accounts payable


92,763



92,571


Accrued expenses


186,295



156,805


Deferred revenue


51,918



50,009


Income taxes payable


29,150



39,166


Short-term debt


-



299,438


Total current liabilities


360,126



637,989


Non-current liabilities:







Deferred income taxes


13,822



9,061


Deferred revenue


53,235



40,281


Other long term liabilities


2,427



1,211


Long-term debt


1,078,611



873,332


Total non-current liabilities


1,148,095



923,885


Total liabilities


1,508,221



1,561,874


STOCKHOLDERS' EQUITY:







Common stock


569



563


Additional paid-in capital


1,379,130



1,303,238


Retained earnings


2,316,237



2,160,299


Treasury stock


(1,546,611)



(1,546,611)


Accumulated other comprehensive income


(189,059)



(222,658)


Total stockholders' equity

$

1,960,266


$

1,694,831


Total liabilities and stockholders' equity

$

3,468,487


$

3,256,705


 

ResMed Inc And Subsidiaries

Condensed Consolidated Statements of Cash Flows (Unaudited - In thousands)











Twelve Months




June 30,




2017



2016


Cash flows from operating activities:







Net income

$

342,284


$

352,409


Adjustment to reconcile net income to cash provided by operating activities:







Depreciation and amortization


112,157



86,849


Impairment of long-lived asset


-



2,815


Stock-based compensation costs


45,925



46,408


Changes in fair value of business combination contingent consideration


10,076



(2,986)


Payment of business combination contingent consideration


(8,460)



-


Impairment of cost-method investments


1,955



750


Changes in operating assets and liabilities, net of effect of acquisitions:







Accounts receivable, net


(63,604)



(27,307)


Inventories, net


(41,599)



30,492


Prepaid expenses, net deferred income taxes and other current assets


(19,257)



12,121


Accounts payable, accrued expenses and other


34,576



46,382


Net cash provided by operating activities


414,053



547,933


Cash flows from investing activities:







Purchases of property, plant and equipment


(62,219)



(58,534)


Patent registration costs


(9,257)



(9,295)


Business acquisitions, net of cash acquired


(7,274)



(1,041,864)


Investments in cost-method investments


(6,464)



(8,965)


Proceeds from sale of business


-



468


Proceeds / (Payments) on maturity of foreign currency contracts


3,324



(7,564)


Net cash used in investing activities


(81,890)



(1,125,754)


Cash flows from financing activities:







Proceeds from issuance of common stock, net


30,161



27,694


Purchases of treasury stock


-



(102,058)


Payment of business combination contingent consideration


(11,682)



(1,228)


Proceeds from borrowings, net of borrowing costs


450,000



1,140,000


Repayment of borrowings


(545,000)



(283,694)


Dividends paid


(186,346)



(168,130)


Net cash (used in) / provided by financing activities


(262,867)



612,584


Effect of exchange rate changes on cash


21,205



(20,578)


Net increase / (decrease) in cash and cash equivalents


90,501



14,185


Cash and cash equivalents at beginning of period


731,434



717,249


Cash and cash equivalents at end of period

$

821,935


$

731,434


 

Reconciliation of Non-GAAP Financial Measures (Unaudited)

(In US$ thousands, except share and per share data)


The measure, "non-GAAP income from operations" is reconciled with GAAP income from operations below:

















Three Months Ended



Twelve Months Ended




June 30,



June 30,




2017



2016



2017



2016


GAAP income from operations

$

127,361


$

118,637


$

425,798


$

428,952


Deferred revenue fair value adjustment (A)


-



2,332



-



2,332


SERVE-HF accrual release (A)


-



(402)



-



(2,804)


Astral battery field safety notification expenses (A)


-



-



5,070



-


Restructuring expenses (A)


-



-



12,358



6,914


Litigation settlement expenses (A)


-



-



8,500



-


Acquisition related expenses (A)


-



1,914



10,076



5,464


Amortization of acquired intangible assets (A)


11,769



12,629



46,578



23,923


Non-GAAP income from operations

$

139,130


$

135,110


$

508,380


$

464,781















The measures "non-GAAP net income" and "non-GAAP diluted earnings per share" are reconciled with GAAP net income and GAAP diluted earnings per share in the table below:



Three Months Ended



Twelve Months Ended




June 30,



June 30,




2017



2016



2017



2016


GAAP net income

$

101,613


$

83,126


$

342,284


$

352,409


Deferred revenue fair value adjustment (A)


-



1,478



-



1,478


SERVE-HF accrual release, net of tax (A)


-



(281)



-



(1,963)


Astral battery field safety notification expenses (A)


-



-



3,549



-


Restructuring expenses, net of tax (A)


-



-



8,295



5,204


Litigation settlement expenses, net of tax (A)


-



-



5,392



-


Acquisition related expenses (A)


-



1,393



10,076



4,943


Amortization of acquired intangible assets, net of tax (A)


7,999



8,794



31,679



17,366


Cumulative ASU 2016-09 income tax benefit not reflected in the quarter ended June 30, 2016 (A)


-



9,905



-



-


Non-GAAP net income (A)

$

109,612


$

104,415


$

401,275


$

379,437


Diluted shares outstanding


143,119



141,654



142,453



141,669


GAAP diluted earnings per share

$

0.71


$

0.59


$

2.40


$

2.49


Non-GAAP diluted earnings per share (A)

$

0.77


$

0.74


$

2.82


$

2.68




(A)

ResMed adjusts for the impact of the Astral battery field safety notification expenses, release of SERVE-HF accrual, restructuring expenses, litigation settlement expenses, one-time deferred revenue fair value adjustment acquisition related expenses and amortization of acquired intangible assets from their evaluation of ongoing operations and believes investors benefit from adjusting these items to facilitate a more meaningful evaluation of current operating performance.




ResMed believes that non-GAAP diluted earnings per share is an additional measure of performance investors can use to compare operating results between reporting periods. ResMed uses non-GAAP information internally in planning, forecasting, and evaluating the results of operations in the current period and in comparing it to past periods. ResMed believes this information provides investors better insight in evaluating ResMed's performance from core operations and provides consistent financial reporting. Our use of non-GAAP measures is intended to supplement, and not to replace, our presentation of net income and other GAAP measures. Like all non-GAAP measures, non-GAAP earnings are subject to inherent limitations because they do not include all the expenses that must be included under GAAP.

 

ResMed Inc. logo.  (PRNewsFoto/ResMed Inc.)

 

SOURCE ResMed Inc.

Media contacts

Global

Alison Graves
(858) 836-6789

Americas

Jayme Rubenstein
(858) 836-6798

EMEA, Japan

Christine Many Lacoste
(33) 04-26-10-02-43

Asia-Pacific

Paul McKeon
(61) 2-8884-2596

ResMed provides a non-transferable, non-exclusive license to the copyrighted images, drawings and materials subject to the following Terms of Use.

All countries & languages